September 26, 2021

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg Capsule

This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for **Selumetinib 10 mg & 25 mg capsule.**

Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For **AstraZeneca Pharma India Limited**

PRATAP RUDRA BHUVANAGIRI

Digitally signed by PRATAP RUDRA BHUVANAGIRI
Date: 2021.09.26 17:27:20 +05'30'

Pratap Rudra
Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628